Attovia Therapeutics, Inc. - 8-K Filing
Attovia Therapeutics reported Q2 financial results, $115.1M cash balance as of June 30, 2026, and provided updates on clinical programs including ATTO-1310's Phase 1b data showing preliminary proof-of-concept for chronic pruritus. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ATTO